Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Clearside Biomedical Inc    CLSD

CLEARSIDE BIOMEDICAL INC (CLSD)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/10/2018 08/13/2018 08/14/2018 08/15/2018 08/16/2018 Date
7.59(c) 7.29(c) 7.2(c) 6.79(c) 6.97(c) Last
246 830 330 220 254 649 336 215 222 638 Volume
+0.40% -3.95% -1.23% -5.69% +2.65% Change
More quotes
Financials (USD)
Sales 2018 -
EBIT 2018 -78,7 M
Net income 2018 -76,7 M
Finance 2018 87,8 M
Yield 2018 -
Sales 2019 4,31 M
EBIT 2019 -80,9 M
Net income 2019 -80,2 M
Finance 2019 20,3 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0
EV / Sales2019 49,4x
Capitalization 233 M
More Financials
Company
Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy.The company was founded by Samir... 
More about the company
Surperformance© ratings of Clearside Biomedical Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on CLEARSIDE BIOMEDICAL INC
08/10CLEARSIDE BIOMEDICAL : to Participate in 2018 Wedbush PacGrow Healthcare Confere..
AQ
08/09Clearside Biomedical to Participate in 2018 Wedbush PacGrow Healthcare Confer..
GL
08/08CLEARSIDE BIOMEDICAL : Management's Discussion and Analysis of Financial Conditi..
AQ
08/08CLEARSIDE BIOMEDICAL, INC. : Results of Operations and Financial Condition, Fina..
AQ
08/08Clearside Biomedical Announces Second Quarter 2018 Financial Results and Prov..
GL
08/08CLEARSIDE BIOMEDICAL INC : Clearside Biomedical, Inc. to Host Earnings Call
AC
08/01CLEARSIDE BIOMEDICAL : to Report Second Quarter 2018 Financial Results on August..
AQ
07/25CLEARSIDE BIOMEDICAL, INC. : Regulation FD Disclosure, Financial Statements and ..
AQ
07/16Clearside Biomedical to Present Data from its Pivotal Phase 3 (“PEACHTR..
GL
07/11Clearside Biomedical Appoints Carol Hoang as Vice President, Medical Affairs
GL
More news
Sector news : Bio Therapeutic Drugs
08/16REGENERON PHARMACEUTICALS : Teva Report Positive Phase 3 Fasinumab Results
DJ
08/03Roche Drug for Brain Disease Granted European Fast-Track
DJ
08/02Regeneron Closes Up 7% After 2Q Earnings Beat -- Data Talk
DJ
08/02REGENERON PHARMACEUTICALS : Beats Earnings Estimates
DJ
07/31UNITED THERAPEUTICS : Medtronic Get FDA OK for Remodulin Implantable System
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
08/13Last year, Daniel White didn't have any hiking experience. Now, with over 2,1..
1
08/13Get the latest ratings for $DCP $KRNT $ITC $CLSD $SIMO in your inbox with Mar.. 
08/13Equities Analysts Offer Predictions for Clearside Biomedical Inc’s Q3 2018 Ea.. 
08/13Wedbush Raises Clearside Biomedical Q3 2018 Earnings Estimates to ($0.50) EPS.. 
08/10Clearside Biomedical $CLSD Posts Quarterly Earnings Results, Misses Expectati.. 
More tweets
Qtime:137
News from SeekingAlpha
08/08Clearside Biomedical Inc. (CLSD) CEO Daniel White on Q2 2018 Results - Earnin.. 
08/08Clearside Biomedical misses by $0.07 
07/16Premarket analyst action - healthcare 
06/17CLEARSIDE BIOMEDICAL : Upside Into Q4 Data And NDA Submission 
06/16INSTITUTIONAL TOP IDEAS : Cormorant Asset Management 
Chart CLEARSIDE BIOMEDICAL INC
Duration : Period :
Clearside Biomedical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CLEARSIDE BIOMEDICAL INC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 23,0 $
Spread / Average Target 219%
EPS Revisions
Managers
NameTitle
Daniel H. White President, Chief Executive Officer & Director
William D. Humphries Chairman
Charles A. Deignan Secretary, Chief Financial & Accounting Officer
Glenn Noronha Chief Scientific Officer
Carol Hoang Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
CLEARSIDE BIOMEDICAL INC-3.00%233
GILEAD SCIENCES7.91%100 220
VERTEX PHARMACEUTICALS17.40%44 961
REGENERON PHARMACEUTICALS-2.59%38 873
NEUROCRINE BIOSCIENCES, INC.49.79%10 514
GENMAB1.46%9 810